The one-trial era: what the FDA’s shift signals for the future of drug development

The article explains a major shift in how the U.S. Food and Drug Administration (FDA) evaluates new medicines. For decades, drug approvals typically required evidence from two large pivotal clinical trials to prove a treatment is safe and effective. Now, the FDA is signaling that in some cases, one strong, well-designed trial—supported by additional evidence—may be enough.

This change doesn’t lower standards. Instead, it reflects advances in science and data analysis. Regulators are increasingly relying on a broader mix of evidence, including real-world data, computer modeling, and a deeper understanding of how drugs work in the body. Together, these tools can strengthen confidence in a treatment without always needing duplicate trials.

The shift has important implications. Drug developers may be able to bring therapies to patients faster and at lower cost, especially in areas like rare diseases or where patient populations are small. However, it also raises expectations: a single trial must now be exceptionally rigorous, and supporting evidence must be strong and well-integrated.

Overall, this “one-trial era” signals a move toward smarter, more flexible drug development, where the quality and totality of evidence matter more than simply the number of trials conducted.